{
  "version": "1.0",
  "created_at": "2026-02-22T14:30:00Z",
  "patient_id": "mpx1016",
  "search_strategy_notes": "Focused 4-query strategy targeting a 43yo female never-smoker with lung adenocarcinoma (signet-ring features), likely advanced disease. Search 1: broad NSCLC recruiting interventional (1069 total). Search 2: lung adenocarcinoma-specific (237 total). Search 3: eligibility-filtered for treatment-naive NSCLC female age 18-43 (3 results). Search 4: first-line advanced adenocarcinoma (2 results). Additional eligibility searches for 'never smoker' and 'signet ring cell' returned 0 results, confirming these are rare-subtype features not explicitly captured in CT.gov eligibility text. Trial selection prioritized: (a) adenocarcinoma-specific trials, (b) first-line/treatment-naive eligibility, (c) trials relevant to never-smoker molecular profile (EGFR, ALK, rare mutations), (d) age and sex compatibility, (e) advanced/metastatic disease stage.",
  "total_searches": 7,
  "total_unique_trials_found": 82,
  "top_trials": [
    {
      "nct_id": "NCT04181060",
      "brief_title": "Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer",
      "relevance_rank": 1,
      "relevance_reasoning": "Highest relevance for this patient profile. This Phase III NCI trial targets first-line treatment of advanced EGFR-mutant non-squamous NSCLC with Osimertinib +/- Bevacizumab. The patient is a 43yo female never-smoker with adenocarcinoma -- the demographic most associated with EGFR-activating mutations (50-60% prevalence in Asian never-smoking females). If molecular testing confirms an EGFR sensitizing mutation (exon 19del, L858R, etc.), this trial is an excellent match. The trial accepts Stage IIIB/IV and recurrent disease, consistent with this patient's imaging findings suggesting advanced disease. No upper age limit, ECOG 0-2 accepted, and no prior systemic treatment required (first-line).",
      "phase": ["PHASE3"],
      "status": "RECRUITING",
      "conditions": [
        "Advanced Lung Non-Squamous Non-Small Cell Carcinoma",
        "Metastatic Lung Non-Squamous Non-Small Cell Carcinoma",
        "Stage IIIB Lung Cancer AJCC v8",
        "Stage IV Lung Cancer AJCC v8"
      ],
      "interventions": ["Osimertinib", "Bevacizumab"],
      "eligibility_summary": "Requires: pathologically confirmed non-squamous NSCLC, advanced/Stage IV disease, somatic activating sensitizing EGFR mutation (exon 19del, L858R, etc.), no prior systemic treatment for metastatic disease, ECOG 0-2, age >= 18, measurable disease per RECIST. No anti-VEGF risk factors (hemoptysis, uncontrolled hypertension, tumor invading major vessels).",
      "potential_disqualifiers": [
        "REQUIRES confirmed EGFR sensitizing mutation -- patient's mutation status is unknown and must be tested",
        "If patient has EGFR exon 20 insertion (non-sensitizing), she is NOT eligible",
        "ECOG performance status must be 0-2 -- patient's PS is unknown",
        "No prior systemic treatment for metastatic disease allowed"
      ]
    },
    {
      "nct_id": "NCT04995523",
      "brief_title": "A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (ARTEMIDE-01)",
      "relevance_rank": 2,
      "relevance_reasoning": "Strong relevance for this patient. AstraZeneca Phase I/II trial of rilvegostomig (anti-TIGIT/anti-PD-1 bispecific) for advanced NSCLC. Parts C and D accept treatment-naive stage IV non-squamous NSCLC (no prior immunotherapy). Critically, the trial EXCLUDES patients with sensitizing EGFR or ALK mutations -- so if molecular testing shows the patient is EGFR/ALK wild-type, this trial becomes highly relevant. The never-smoker adenocarcinoma profile with signet-ring features could be wild-type, and this novel immunotherapy approach could be a good option. Requires PD-L1 expression documentation. Wide age range (18-130), global trial with 48 locations.",
      "phase": ["PHASE1", "PHASE2"],
      "status": "RECRUITING",
      "conditions": ["Non-Small-Cell Lung Carcinoma"],
      "interventions": ["AZD2936 (rilvegostomig)"],
      "eligibility_summary": "Parts C/D (first-line): Stage IV squamous or non-squamous NSCLC, no prior I/O treatment for metastatic NSCLC, documented PD-L1 expression, ECOG 0-1, measurable disease per RECIST v1.1, adequate organ function, life expectancy >= 12 weeks. Part C allows one prior chemo line.",
      "potential_disqualifiers": [
        "EXCLUDES sensitizing EGFR mutations or ALK fusions -- patient needs molecular testing first",
        "EXCLUDES other known genomic alterations with approved first-line targeted therapy (ROS1, NTRK, BRAF V600E)",
        "Requires documented PD-L1 expression -- patient's PD-L1 status unknown",
        "ECOG must be 0-1 -- patient's performance status unknown",
        "Symptomatic CNS metastases excluded"
      ]
    },
    {
      "nct_id": "NCT06563999",
      "brief_title": "Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations (NUMER)",
      "relevance_rank": 3,
      "relevance_reasoning": "Highly relevant if patient has a rare driver mutation. This Phase II umbrella trial from Sun Yat-sen University targets treatment-naive unresectable stage III NSCLC with rare mutations (EGFR exon20ins, ROS1, RET, NTRK, MET exon14, HER2, BRAF V600E, KRAS G12C, ALK). Signet-ring cell adenocarcinoma in a young never-smoker has elevated probability of harboring rare oncogenic drivers. The trial uses NGS-directed targeted therapy to convert unresectable to resectable disease. If the patient's disease is stage III (possible given bilateral involvement without confirmed distant metastases) and NGS reveals a rare mutation, this trial offers a precision medicine approach uniquely suited to her profile.",
      "phase": ["PHASE2"],
      "status": "RECRUITING",
      "conditions": ["Lung Cancer Stage III", "Mutation"],
      "interventions": [
        "Sunvozertinib",
        "Crizotinib",
        "Pralsetinib",
        "Larotrectinib",
        "Savolitinib",
        "Pyrotinib",
        "Dabrafenib+Trametinib",
        "Glecirasib",
        "Ensartinib"
      ],
      "eligibility_summary": "Requires: treatment-naive unresectable stage III NSCLC, rare mutation confirmed by NGS (EGFR exon20ins, ROS1 fusion, RET fusion, NTRK fusion, MET exon14 skip, HER2, BRAF V600E, KRAS G12C, ALK fusion), ECOG 0-1, adequate organ function, age 18-75. Must NOT have EGFR exon 19del or L858R sensitizing mutations.",
      "potential_disqualifiers": [
        "REQUIRES confirmed rare mutation by NGS -- patient's molecular profile is unknown",
        "REQUIRES unresectable stage III disease -- patient's stage is unknown, may be stage IV",
        "If patient has common EGFR sensitizing mutations (exon 19del, L858R), she is NOT eligible",
        "Treatment-naive only -- no prior systemic treatment allowed",
        "Single site in Guangzhou, China -- geographic access issue",
        "ECOG performance status must be 0-1 -- unknown for this patient"
      ]
    },
    {
      "nct_id": "NCT07288177",
      "brief_title": "Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer (RAINFOL-05)",
      "relevance_rank": 4,
      "relevance_reasoning": "Relevant as a later-line option or if patient progresses on initial therapy. This Phase 2 Genmab trial evaluates rinatabart sesutecan (Rina-S), a novel antibody-drug conjugate (ADC), specifically in adenocarcinoma histology NSCLC. Notably, it REQUIRES adenocarcinoma histology (excludes squamous), directly matching this patient's diagnosis. It accepts patients with or without actionable genetic alterations (AGAs), making it suitable regardless of molecular testing results. The trial explicitly targets locally advanced or metastatic disease. However, it requires disease progression on at least one prior regimen, so it would be relevant if the patient has received prior treatment or as a future option.",
      "phase": ["PHASE2"],
      "status": "RECRUITING",
      "conditions": ["Non-small Cell Lung Cancer (NSCLC)"],
      "interventions": ["Rinatabart Sesutecan (Rina-S)"],
      "eligibility_summary": "Requires: histologically confirmed metastatic or locally advanced NSCLC of adenocarcinoma histology, disease progression on or after most recent regimen, measurable disease per RECIST v1.1, ECOG 0-1, age >= 18. Accepts patients with or without actionable genetic alterations.",
      "potential_disqualifiers": [
        "REQUIRES prior treatment with disease progression -- patient appears treatment-naive",
        "ECOG must be 0-1 -- patient's performance status unknown",
        "Excludes unstable/symptomatic brain metastases and leptomeningeal disease",
        "Very early in recruitment (started Jan 2026, only 2 sites so far) -- limited access"
      ]
    },
    {
      "nct_id": "NCT05549037",
      "brief_title": "Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC (PACIFIC15)",
      "relevance_rank": 5,
      "relevance_reasoning": "Relevant as a first-line treatment option for advanced NSCLC. This Phase III trial from Hunan Province Tumor Hospital evaluates whether time-of-day of immunochemotherapy administration (pembrolizumab or sintilimab + chemotherapy) affects PFS in treatment-naive advanced NSCLC. The trial accepts treatment-naive patients aged 18-75, with specific exclusions for EGFR/ALK/ROS1 mutations. If the patient is confirmed EGFR/ALK/ROS1 wild-type, this provides a standard-of-care immunochemotherapy option. The patient's age (43) and sex (female) fit inclusion. The trial is relevant because pembrolizumab + chemotherapy is the current standard first-line treatment for advanced non-driver-mutated NSCLC, and even if the trial question (chronotherapy) is narrow, the patient receives standard-of-care treatment.",
      "phase": ["PHASE3"],
      "status": "RECRUITING",
      "conditions": ["Non-small Cell Lung Cancer"],
      "interventions": ["Pembrolizumab", "Sintilimab", "Platinum-based chemotherapy"],
      "eligibility_summary": "Requires: histopathology-confirmed locally advanced or metastatic NSCLC, treatment-naive (no prior systemic therapy), EGFR/ALK/ROS1 mutation-negative, ECOG 0-1, predicted survival >= 12 weeks, measurable lesion per RECIST 1.1, age 18-75. Stable brain metastases allowed.",
      "potential_disqualifiers": [
        "REQUIRES EGFR, ALK, and ROS1 mutations to be negative -- patient's molecular profile unknown",
        "ECOG must be 0-1 -- patient's performance status unknown",
        "Single site in Changsha, China -- geographic access limitation",
        "Max age 75 (not an issue for this 43yo patient)",
        "Excludes prior systemic therapy -- consistent with treatment-naive patient",
        "Excludes spinal cord compression, meningeal metastasis, active interstitial lung disease"
      ]
    }
  ],
  "search_queries_used": [
    {
      "query_params": {
        "tool": "search_trials",
        "condition": "non-small cell lung cancer",
        "status": ["RECRUITING"],
        "study_type": "INTERVENTIONAL",
        "page_size": 20,
        "count_total": true
      },
      "results_count": 1069,
      "notes": "Broad NSCLC search to establish baseline of recruiting interventional trials. Returned diverse mix of Phase I-III trials across targeted therapy, immunotherapy, ADCs, and novel agents."
    },
    {
      "query_params": {
        "tool": "search_trials",
        "condition": "lung adenocarcinoma",
        "status": ["RECRUITING"],
        "study_type": "INTERVENTIONAL",
        "page_size": 20,
        "count_total": true
      },
      "results_count": 237,
      "notes": "Adenocarcinoma-specific search. Smaller result set with more histology-specific trials. Identified NCT07423169 (partial tumor irradiation for lung adenocarcinoma) and several ADC trials."
    },
    {
      "query_params": {
        "tool": "search_by_eligibility",
        "condition": "NSCLC",
        "eligibility_keywords": "never smoker",
        "sex": "FEMALE",
        "min_age": "18 Years",
        "max_age": "43 Years"
      },
      "results_count": 0,
      "notes": "No trials specifically mention 'never smoker' in eligibility criteria within CT.gov structured fields. Smoking status is rarely an explicit eligibility criterion; instead, it correlates with molecular subtypes (EGFR, ALK) which ARE eligibility criteria."
    },
    {
      "query_params": {
        "tool": "search_by_eligibility",
        "condition": "non-small cell lung cancer",
        "eligibility_keywords": "signet ring cell"
      },
      "results_count": 0,
      "notes": "No trials specifically target signet-ring cell NSCLC. This confirms it is a rare histological subtype not captured in trial eligibility criteria. Broader adenocarcinoma trials would be applicable."
    },
    {
      "query_params": {
        "tool": "search_by_eligibility",
        "condition": "non-small cell lung cancer",
        "eligibility_keywords": "treatment naive",
        "sex": "FEMALE",
        "min_age": "18 Years",
        "max_age": "43 Years"
      },
      "results_count": 3,
      "notes": "Targeted search for treatment-naive NSCLC trials accepting 43yo females. Found 3 highly relevant trials including NCT04995523 (AZD2936 TIGIT/PD-1 bispecific) and NCT06563999 (rare mutation umbrella)."
    },
    {
      "query_params": {
        "tool": "search_trials",
        "condition": "NSCLC adenocarcinoma",
        "status": ["RECRUITING"],
        "study_type": "INTERVENTIONAL",
        "intervention": "immunotherapy",
        "page_size": 15
      },
      "results_count": 15,
      "notes": "Combined adenocarcinoma + immunotherapy search. Found NCT02133196 (TIL therapy at NCI), NCT07288177 (Rina-S ADC for adenocarcinoma specifically), and several checkpoint inhibitor combination trials."
    },
    {
      "query_params": {
        "tool": "search_by_eligibility",
        "condition": "lung adenocarcinoma",
        "eligibility_keywords": "first line advanced",
        "page_size": 20
      },
      "results_count": 20,
      "notes": "First-line advanced lung adenocarcinoma eligibility search. Confirmed NCT05549037 (chronotherapy immunochemotherapy) and NCT05208944 (THIO + cemiplimab) as relevant first-line options."
    }
  ]
}
